| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $12,749,900 ) (Continued on the next page) |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 00 | 16 | HRSA | 8/6/2026 | $100,746 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R21AG098515 | Sex-specific role of Akkermansia muciniphila in hypertension | 000 | 1 | NIH | 9/7/2026 | $401,618 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R56DA066988 | Photoaffinity and Multi-Omic Analysis of Targets Pathways Driving Synthetic Opioid-Induced Toxicity and Reversal | 000 | 1 | NIH | 9/4/2026 | $455,827 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R00GM159057 | Induced-Proximity Platform to Control Cellular Signaling and Proteostasis | 000 | 2 | NIH | 8/21/2026 | $248,999 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R21CA292033 | Novel selective allosteric modulators of PTHrP/PTH receptor to inhibit prostate cancer metastases | 000 | 1 | NIH | 4/28/2026 | $418,822 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01AI201788 | Identification of immunoprotective antigens for preventing Lyme disease | 000 | 1 | NIH | 8/28/2026 | $768,796 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | K22AI179938 | Elucidating the Cardioprotective Role of Fetal-derived CD8+ T Cells During Viral-induced Myocarditis | 000 | 2 | NIH | 8/19/2026 | $107,997 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HL171401 | Conjugated bile acids as nutritionally re-programmable antihypertensive metabolites | 000 | 3 | NIH | 7/21/2026 | $736,484 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA287731 | Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer | 001 | 3 | NIH | 8/28/2026 | $1,675,569 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01AG083628 | Investigation of active kinome networks in Alzheimer's dementia. | 000 | 3 | NIH | 6/9/2026 | $736,899 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 001 | 5 | NIH | 3/30/2026 | $53,314 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HD104418 | Astrocyte insulin resistance-induced neuroendocrine defects in pubertal delay and hypogonadotropic hypogonadism | 000 | 5 | NIH | 1/16/2026 | $479,823 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA276732 | Engineering Exosome for Pancreatic Cancer Targeting Therapies | 000 | 4 | NIH | 8/27/2026 | $496,344 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HL175306 | Building a kidney monitoring panel to guide therapy in resistant hypertension | 000 | 3 | NIH | 7/9/2026 | $647,077 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA272760 | Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence | 000 | 4 | NIH | 3/27/2026 | $374,135 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HL178459 | Novel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammation | 001 | 2 | NIH | 3/25/2026 | $17,384 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01HL178459 | Novel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammation | 000 | 2 | NIH | 3/5/2026 | $550,490 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01DK133203 | Role of GSK3beta in diabetic kidney disease | 000 | 5 | NIH | 6/5/2026 | $339,900 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | U01DA054330 | Cross platform analysis of drug targets and toxicity of bath salts | 000 | 5 | NIH | 6/26/2026 | $500,993 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01AA029674 | Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies | 000 | 5 | NIH | 6/1/2026 | $419,701 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01ES036248 | Developmental pyrethroid exposure in the prairie vole as a model of environmental risk for autism | 000 | 2 | NIH | 2/5/2026 | $592,124 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R00DA055064 | Investigating the long-term effects of prenatal circadian rhythm disruption on substance use-related disorders | 000 | 4 | NIH | 2/9/2026 | $247,843 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01DK134053 | Role of neutrophil extracellular traps (NETs) in Inflammatory bowel disease | 000 | 4 | NIH | 1/14/2026 | $430,127 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA288278 | Molecular basis and targeting of FASN in expanding PARPi utility for TNBC | 001 | 2 | NIH | 4/17/2026 | $52,512 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA288278 | Molecular basis and targeting of FASN in expanding PARPi utility for TNBC | 000 | 2 | NIH | 2/10/2026 | $472,607 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 01 | 25 | HRSA | 5/21/2026 | $433,334 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 00 | 25 | HRSA | 3/25/2026 | $86,666 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H1224838 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 03 | 13 | HRSA | 7/9/2026 | $0 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H1224838 | Ryan White Title IV Women, Infants, Children, Youth and Affected Family Members AIDS Healthcare | 02 | 13 | HRSA | 6/23/2026 | $96,871 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614 | LUCAS | USA | T03OH008605 | NIOSH Training Project Grant (TPG): Industrial Hygiene - University of Toledo | 00 | 20 | CDC | 8/17/2026 | $63,896 |
| | 2026 | 2026 | UNIVERSITY OF TOLEDO | 3000 Arlington Ave | Toledo | OH | 43614 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 00 | 16 | HRSA | 8/6/2026 | $1,373,013 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 03 | 24 | HRSA | 12/11/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | T03OH008605 | NIOSH Training Project Grant (TPG): Industrial Hygiene - University of Toledo | 02 | 19 | CDC | 11/13/2025 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA287731 | Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer | 000 | 2 | NIH | 8/27/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R56MH139698 | Serotonin-mediated reorganization of the adolescent medial prefrontal cortex | 000 | 1 | NIH | 4/9/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01AG071332 | PPARG regulates osteocyte bioenergetics and function during aging | 000 | 5 | NIH | 3/17/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01DK124098 | Gut-brain axis in Parkinson's Disease | 001 | 5 | NIH | 8/10/2026 | -$495,952 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01DK124098 | Gut-brain axis in Parkinson's Disease | 000 | 5 | NIH | 4/30/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01NS122534 | Pre and post-synaptic pathways underlying the stress response in the adrenal medulla | 000 | 10 | NIH | 3/5/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R03CA286634 | TAZ-driven Regulation of Tumor Microenvironment in Triple-Negative Breast Cancer | 000 | 3 | NIH | 4/29/2026 | -$1 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 001 | 1 | NIH | 7/17/2026 | -$1 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA286189 | Dormancy mimicking to inhibit prostate cancer metastasis progression and recurrence | 000 | 1 | NIH | 7/15/2026 | $1 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | H7600732 | Ryan White Part C Outpatient EIS Program | 04 | 24 | HRSA | 1/16/2026 | $0 |
| | 2026 | 2025 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | U7723072 | Area Health Education Centers Point of Service Maintenance and Enhancement | 02 | 15 | HRSA | 1/5/2026 | $0 |
| | 2026 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614-3390 | LUCAS | USA | T03OH008605 | NIOSH Training Project Grant (TPG): Industrial Hygiene - University of Toledo | 02 | 19 | CDC | 11/13/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R21ES036352 | Developmental pyrethroid exposure in the Shank3 mutant prairie vole as a 2-hit model for neurodevelopmental disorder risk | 000 | 1 | NIH | 7/15/2026 | $0 |
| | 2026 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R21CA277252 | Targeting FASN to eliminate metastatic breast cancer in the brain | 000 | 2 | NIH | 12/3/2025 | $0 |
| | 2026 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R21DA055558 | Zebrafish Screens to Identify Agents which Reverse the Effects of Synthetic Opioids | 000 | 2 | NIH | 2/11/2026 | -$2,503 |
| | 2026 | 2024 | UNIVERSITY OF TOLEDO | 3000 ARLINGTON AVE | TOLEDO | OH | 43614 | LUCAS | USA | R01CA258682 | Targeting eIF4A1 in drug-resistant breast cancer stem-like cells | 001 | 3 | NIH | 7/22/2026 | -$3,352 |
|
